NASDAQ:TARS

Tarsus Pharmaceuticals Competitors

$29.30
+0.74 (+2.59 %)
(As of 04/13/2021 03:45 AM ET)
Add
Compare
Today's Range
$28.44
Now: $29.30
$29.61
50-Day Range
$27.37
MA: $32.35
$40.15
52-Week Range
$15.32
Now: $29.30
$63.69
Volume983 shs
Average Volume38,851 shs
Market Capitalization$600.74 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A

Competitors

Tarsus Pharmaceuticals (NASDAQ:TARS) Vs. SRNE, BLUE, RUBY, NK, BCRX, and SGMO

Should you be buying TARS stock or one of its competitors? Companies in the industry of "biological products, except diagnostic" are considered alternatives and competitors to Tarsus Pharmaceuticals, including Sorrento Therapeutics (SRNE), bluebird bio (BLUE), Rubius Therapeutics (RUBY), NantKwest (NK), BioCryst Pharmaceuticals (BCRX), and Sangamo Therapeutics (SGMO).

Tarsus Pharmaceuticals (NASDAQ:TARS) and Sorrento Therapeutics (NASDAQ:SRNE) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their analyst recommendations, earnings, institutional ownership, valuation, dividends, risk and profitability.

Analyst Recommendations

This is a breakdown of current recommendations for Tarsus Pharmaceuticals and Sorrento Therapeutics, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Tarsus Pharmaceuticals00413.20
Sorrento Therapeutics00403.00

Tarsus Pharmaceuticals currently has a consensus price target of $37.25, suggesting a potential upside of 27.13%. Sorrento Therapeutics has a consensus price target of $28.75, suggesting a potential upside of 316.67%. Given Sorrento Therapeutics' higher probable upside, analysts clearly believe Sorrento Therapeutics is more favorable than Tarsus Pharmaceuticals.

Profitability

This table compares Tarsus Pharmaceuticals and Sorrento Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Tarsus PharmaceuticalsN/AN/AN/A
Sorrento Therapeutics-698.01%-314.06%-43.60%

Valuation and Earnings

This table compares Tarsus Pharmaceuticals and Sorrento Therapeutics' gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Tarsus PharmaceuticalsN/AN/AN/AN/AN/A
Sorrento Therapeutics$31.43 million62.55$-292,070,000.00($2.12)-3.30

Tarsus Pharmaceuticals has higher earnings, but lower revenue than Sorrento Therapeutics.

Insider and Institutional Ownership

27.4% of Sorrento Therapeutics shares are owned by institutional investors. 3.4% of Sorrento Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Summary

Tarsus Pharmaceuticals beats Sorrento Therapeutics on 5 of the 9 factors compared between the two stocks.

bluebird bio (NASDAQ:BLUE) and Tarsus Pharmaceuticals (NASDAQ:TARS) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, analyst recommendations, earnings, valuation, risk, profitability and dividends.

Analyst Ratings

This is a breakdown of recent ratings and target prices for bluebird bio and Tarsus Pharmaceuticals, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
bluebird bio012602.33
Tarsus Pharmaceuticals00413.20

bluebird bio presently has a consensus price target of $61.40, indicating a potential upside of 121.34%. Tarsus Pharmaceuticals has a consensus price target of $37.25, indicating a potential upside of 27.13%. Given bluebird bio's higher probable upside, equities analysts plainly believe bluebird bio is more favorable than Tarsus Pharmaceuticals.

Earnings and Valuation

This table compares bluebird bio and Tarsus Pharmaceuticals' top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
bluebird bio$44.67 million42.10$-789,610,000.00($14.31)-1.96
Tarsus PharmaceuticalsN/AN/AN/AN/AN/A

Tarsus Pharmaceuticals has lower revenue, but higher earnings than bluebird bio.

Profitability

This table compares bluebird bio and Tarsus Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
bluebird bio-256.84%-45.78%-35.14%
Tarsus PharmaceuticalsN/AN/AN/A

Institutional and Insider Ownership

94.3% of bluebird bio shares are held by institutional investors. 3.6% of bluebird bio shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Rubius Therapeutics (NASDAQ:RUBY) and Tarsus Pharmaceuticals (NASDAQ:TARS) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, earnings, analyst recommendations, valuation, institutional ownership, dividends and risk.

Analyst Recommendations

This is a breakdown of recent recommendations for Rubius Therapeutics and Tarsus Pharmaceuticals, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Rubius Therapeutics03102.25
Tarsus Pharmaceuticals00413.20

Rubius Therapeutics currently has a consensus target price of $23.3333, indicating a potential downside of 3.10%. Tarsus Pharmaceuticals has a consensus target price of $37.25, indicating a potential upside of 27.13%. Given Tarsus Pharmaceuticals' stronger consensus rating and higher possible upside, analysts plainly believe Tarsus Pharmaceuticals is more favorable than Rubius Therapeutics.

Insider & Institutional Ownership

93.7% of Rubius Therapeutics shares are held by institutional investors. 58.4% of Rubius Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Earnings & Valuation

This table compares Rubius Therapeutics and Tarsus Pharmaceuticals' top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Rubius TherapeuticsN/AN/A$-163,460,000.00($2.08)-11.58
Tarsus PharmaceuticalsN/AN/AN/AN/AN/A

Profitability

This table compares Rubius Therapeutics and Tarsus Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Rubius TherapeuticsN/A-77.33%-49.05%
Tarsus PharmaceuticalsN/AN/AN/A

Summary

Tarsus Pharmaceuticals beats Rubius Therapeutics on 6 of the 8 factors compared between the two stocks.

Tarsus Pharmaceuticals (NASDAQ:TARS) and NantKwest (NASDAQ:NK) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, dividends, valuation, risk, analyst recommendations, earnings and profitability.

Profitability

This table compares Tarsus Pharmaceuticals and NantKwest's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Tarsus PharmaceuticalsN/AN/AN/A
NantKwest-76,658.58%-56.06%-46.93%

Insider and Institutional Ownership

9.4% of NantKwest shares are owned by institutional investors. 71.7% of NantKwest shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Analyst Ratings

This is a summary of recent ratings for Tarsus Pharmaceuticals and NantKwest, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Tarsus Pharmaceuticals00413.20
NantKwest00103.00

Tarsus Pharmaceuticals currently has a consensus target price of $37.25, suggesting a potential upside of 27.13%. NantKwest has a consensus target price of $18.00, suggesting a potential upside of 11.87%. Given Tarsus Pharmaceuticals' stronger consensus rating and higher possible upside, analysts plainly believe Tarsus Pharmaceuticals is more favorable than NantKwest.

Earnings and Valuation

This table compares Tarsus Pharmaceuticals and NantKwest's gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Tarsus PharmaceuticalsN/AN/AN/AN/AN/A
NantKwest$40,000.0043,984.03$-65,790,000.00($0.70)-22.99

Tarsus Pharmaceuticals has higher earnings, but lower revenue than NantKwest.

Summary

Tarsus Pharmaceuticals beats NantKwest on 7 of the 10 factors compared between the two stocks.

Tarsus Pharmaceuticals (NASDAQ:TARS) and BioCryst Pharmaceuticals (NASDAQ:BCRX) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, dividends, earnings, analyst recommendations, profitability, institutional ownership and risk.

Profitability

This table compares Tarsus Pharmaceuticals and BioCryst Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Tarsus PharmaceuticalsN/AN/AN/A
BioCryst Pharmaceuticals-233.45%-328.70%-71.11%

Institutional & Insider Ownership

72.0% of BioCryst Pharmaceuticals shares are owned by institutional investors. 4.3% of BioCryst Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Valuation & Earnings

This table compares Tarsus Pharmaceuticals and BioCryst Pharmaceuticals' gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Tarsus PharmaceuticalsN/AN/AN/AN/AN/A
BioCryst Pharmaceuticals$48.83 million34.94$-108,900,000.00($0.94)-10.22

Tarsus Pharmaceuticals has higher earnings, but lower revenue than BioCryst Pharmaceuticals.

Analyst Ratings

This is a summary of recent ratings and price targets for Tarsus Pharmaceuticals and BioCryst Pharmaceuticals, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Tarsus Pharmaceuticals00413.20
BioCryst Pharmaceuticals03802.73

Tarsus Pharmaceuticals presently has a consensus target price of $37.25, suggesting a potential upside of 27.13%. BioCryst Pharmaceuticals has a consensus target price of $12.3333, suggesting a potential upside of 29.14%. Given BioCryst Pharmaceuticals' higher probable upside, analysts clearly believe BioCryst Pharmaceuticals is more favorable than Tarsus Pharmaceuticals.

Tarsus Pharmaceuticals (NASDAQ:TARS) and Sangamo Therapeutics (NASDAQ:SGMO) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their earnings, dividends, analyst recommendations, valuation, profitability, risk and institutional ownership.

Institutional and Insider Ownership

57.7% of Sangamo Therapeutics shares are owned by institutional investors. 1.8% of Sangamo Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Profitability

This table compares Tarsus Pharmaceuticals and Sangamo Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Tarsus PharmaceuticalsN/AN/AN/A
Sangamo Therapeutics-51.51%-16.32%-9.85%

Earnings and Valuation

This table compares Tarsus Pharmaceuticals and Sangamo Therapeutics' gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Tarsus PharmaceuticalsN/AN/AN/AN/AN/A
Sangamo Therapeutics$102.43 million15.64$-95,190,000.00($0.85)-13.12

Tarsus Pharmaceuticals has higher earnings, but lower revenue than Sangamo Therapeutics.

Analyst Recommendations

This is a summary of recent ratings and recommmendations for Tarsus Pharmaceuticals and Sangamo Therapeutics, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Tarsus Pharmaceuticals00413.20
Sangamo Therapeutics02402.67

Tarsus Pharmaceuticals presently has a consensus target price of $37.25, suggesting a potential upside of 27.13%. Sangamo Therapeutics has a consensus target price of $20.20, suggesting a potential upside of 82.15%. Given Sangamo Therapeutics' higher probable upside, analysts plainly believe Sangamo Therapeutics is more favorable than Tarsus Pharmaceuticals.

Summary

Tarsus Pharmaceuticals beats Sangamo Therapeutics on 5 of the 9 factors compared between the two stocks.


Tarsus Pharmaceuticals Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
Sorrento Therapeutics logo
SRNE
Sorrento Therapeutics
1.3$7.00+0.9%$1.95 billion$31.43 million-4.79News Coverage
bluebird bio logo
BLUE
bluebird bio
1.8$28.01+0.1%$1.88 billion$44.67 million-2.55
Rubius Therapeutics logo
RUBY
Rubius Therapeutics
1.6$24.08+7.6%$1.81 billionN/A-11.25Decrease in Short Interest
Gap Up
NantKwest logo
NK
NantKwest
1.3$16.09+4.8%$1.76 billion$40,000.00-22.66
BioCryst Pharmaceuticals logo
BCRX
BioCryst Pharmaceuticals
1.7$9.61+1.1%$1.69 billion$48.83 million-12.64
Sangamo Therapeutics logo
SGMO
Sangamo Therapeutics
1.3$11.15+0.8%$1.59 billion$102.43 million-18.58Analyst Upgrade
Krystal Biotech logo
KRYS
Krystal Biotech
1.5$71.94+1.3%$1.58 billionN/A-48.61
Immunovant logo
IMVT
Immunovant
1.8$15.25+0.1%$1.50 billionN/A-11.82Increase in Short Interest
AlloVir logo
ALVR
AlloVir
1.4$22.76+0.0%$1.48 billionN/A0.00Increase in Short Interest
REGENXBIO logo
RGNX
REGENXBIO
1.6$35.11+3.9%$1.43 billion$35.23 million-14.16Increase in Short Interest
Gap Down
Kymera Therapeutics logo
KYMR
Kymera Therapeutics
1.2$30.93+1.6%$1.41 billionN/A0.00Insider Selling
Increase in Short Interest
News Coverage
Replimune Group logo
REPL
Replimune Group
1.5$29.09+0.9%$1.36 billionN/A-16.44News Coverage
Alector logo
ALEC
Alector
1.3$17.30+2.9%$1.34 billion$21.22 million-7.76
C4 Therapeutics logo
CCCC
C4 Therapeutics
1.4$31.11+1.3%$1.32 billionN/A0.00Increase in Short Interest
Translate Bio logo
TBIO
Translate Bio
1.6$17.51+2.2%$1.29 billion$7.80 million-16.36
Ocugen logo
OCGN
Ocugen
1.1$6.73+0.7%$1.26 billionN/A-4.55Increase in Short Interest
Atara Biotherapeutics logo
ATRA
Atara Biotherapeutics
1.4$13.65+0.4%$1.15 billionN/A-2.95
Forma Therapeutics logo
FMTX
Forma Therapeutics
1.8$28.42+4.0%$1.12 billion$100.56 million0.00Increase in Short Interest
Mesoblast logo
MESO
Mesoblast
1.4$8.58+1.5%$1.10 billion$32.16 million-9.75Decrease in Short Interest
Vaxcyte logo
PCVX
Vaxcyte
1.7$20.13+0.1%$1.03 billionN/A0.00Increase in Short Interest
Coherus BioSciences logo
CHRS
Coherus BioSciences
1.4$13.85+1.1%$997.28 million$356.07 million6.79Unusual Options Activity
News Coverage
Curis logo
CRIS
Curis
1.3$10.43+3.7%$990.24 million$10 million-12.72Increase in Short Interest
Gap Down
Scholar Rock logo
SRRK
Scholar Rock
1.5$28.50+2.3%$953.88 million$20.49 million-11.83Increase in Short Interest
Taysha Gene Therapies logo
TSHA
Taysha Gene Therapies
1.8$24.71+1.2%$944.03 millionN/A0.00Analyst Report
News Coverage
Gap Down
Cortexyme logo
CRTX
Cortexyme
1.3$32.98+3.3%$942.12 millionN/A-13.74Gap Down
Black Diamond Therapeutics logo
BDTX
Black Diamond Therapeutics
1.6$25.30+2.2%$894.42 millionN/A-4.18Increase in Short Interest
Adverum Biotechnologies logo
ADVM
Adverum Biotechnologies
1.7$9.01+0.7%$887.01 million$250,000.00-7.09News Coverage
Sutro Biopharma logo
STRO
Sutro Biopharma
1.3$19.30+0.0%$885.72 million$42.74 million-214.44Increase in Short Interest
News Coverage
Aerie Pharmaceuticals logo
AERI
Aerie Pharmaceuticals
1.7$18.18+1.3%$863.74 million$69.89 million-4.34
Passage Bio logo
PASG
Passage Bio
1.8$16.33+2.1%$860.76 millionN/A0.00Increase in Short Interest
Gap Down
TCR2 Therapeutics logo
TCRR
TCR2 Therapeutics
1.6$22.30+1.2%$840.16 millionN/A-9.21Analyst Report
Increase in Short Interest
Aligos Therapeutics logo
ALGS
Aligos Therapeutics
1.5$21.63+1.3%$813.97 millionN/A0.00Lockup Expiration
Orchard Therapeutics logo
ORTX
Orchard Therapeutics
1.6$6.51+0.8%$811.44 million$2.51 million-3.95
Cellectis logo
CLLS
Cellectis
1.3$19.45+4.1%$798.28 million$22.99 million-10.35
Adaptimmune Therapeutics logo
ADAP
Adaptimmune Therapeutics
1.5$4.95+0.4%$772.67 million$1.12 million-5.00Increase in Short Interest
Inhibrx logo
INBX
Inhibrx
1.6$20.67+4.0%$749.30 millionN/A0.00Decrease in Short Interest
Gap Down
Harpoon Therapeutics logo
HARP
Harpoon Therapeutics
1.5$20.02+1.1%$656.00 million$5.78 million-9.40Increase in Short Interest
DBV Technologies logo
DBVT
DBV Technologies
1.2$5.85+2.9%$624.08 million$14.75 million-2.51Increase in Short Interest
Gap Down
Athira Pharma logo
ATHA
Athira Pharma
2.2$17.02+1.3%$623.62 millionN/A0.00Analyst Upgrade
Vaxart logo
VXRT
Vaxart
1.3$5.37+2.8%$614.74 million$9.86 million-9.10
MeiraGTx logo
MGTX
MeiraGTx
1.4$13.17+0.7%$578.97 million$13.29 million-9.34
Compugen logo
CGEN
Compugen
1.4$8.49+3.3%$561.73 million$17.80 million-22.95News Coverage
Agenus logo
AGEN
Agenus
1.6$2.65+0.8%$547.53 million$150.05 million-2.43
Oyster Point Pharma logo
OYST
Oyster Point Pharma
1.0$20.67+0.9%$533.23 millionN/A-5.96News Coverage
Poseida Therapeutics logo
PSTX
Poseida Therapeutics
1.8$8.42+1.0%$527.92 millionN/A-1.23
Solid Biosciences logo
SLDB
Solid Biosciences
1.8$4.83+1.0%$521.57 millionN/A-2.34Increase in Short Interest
Precision BioSciences logo
DTIL
Precision BioSciences
1.5$8.62+3.0%$476.40 million$22.24 million-4.29Increase in Short Interest
AVROBIO logo
AVRO
AVROBIO
1.7$10.95+3.1%$469.91 millionN/A-3.32
Freeline Therapeutics logo
FRLN
Freeline Therapeutics
1.6$12.80+3.4%$459.17 millionN/A0.00Gap Up
Aptose Biosciences logo
APTO
Aptose Biosciences
1.4$5.04+0.2%$448.64 millionN/A-7.88Increase in Short Interest
This page was last updated on 4/13/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.